Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus envofolimab as second-line therapy for unresectable advanced biliary tract tumors (single-arm phase 2)
ChiCTR2300069715Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and envafolimab in biliary adenocarcinoma, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 1 more, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Progression-free survival. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
surufatinibenvafolimab
03
Conditions
biliary adenocarcinomaintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2300069715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069715.